Across TCGA pan-cancer cohorts, RAB26 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RAB26 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RAB26 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB26 expression acts as an unfavorable survival marker.
KIRC and LGG are the cancer types where RAB26 Mutation most reproducibly stratifies survival.